New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
07:04 EDTMDCO, BSXBoston Scientific and The Medicines Co. announce U.S. co-promotion agreement
Boston Scientific (BSX) and The Medicines Company (MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional support for the Promus PREMIER Stent System in U.S. hospitals beginning January 1, 2014.
News For BSX;MDCO From The Last 14 Days
Check below for free stories on BSX;MDCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
07:22 EDTMDCOThe Medicines Co. to acquire Tenaxis for $58M
The Medicines Company and Tenaxis Medical announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received U.S. PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a European CE Mark as a surgical sealant applicable to cardiovascular, general, urological, and thoracic surgery. Under the terms of the agreement, The Medicines Company will pay $58M upfront on closing of the deal. The Medicines Company will also pay milestone payments of up to $112M contingent upon achieving certain commercial and -- in pursuit of even broader indications -- regulatory approval milestones.
07:08 EDTMDCOThe Medicines Co. reports Q1 adjusted EPS 33c, may not compare to consensus (7c)
Subscribe for More Information
April 22, 2014
09:30 EDTBSXBoston Scientific begins trial of ACUITY X4 LV pacing leads
Boston Scientific has conducted the first implant in the clinical trial of the next generation ACUITY X4 left-ventricular pacing leads and RELIANCE™ 4-FRONT defibrillation leads. The clinical trial is designed to establish the safety and effectiveness of both lead families and is intended to support U.S. Food and Drug Administration approval of these devices.
April 17, 2014
09:59 EDTMDCOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:17 EDTMDCOThe Medicines Co. downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information
April 16, 2014
15:39 EDTBSXBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
April 15, 2014
16:47 EDTBSXBoston Scientific announces FDA approval for defibrillators
Subscribe for More Information
11:53 EDTBSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Subscribe for More Information
09:23 EDTBSXBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2014
10:02 EDTBSXOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
April 10, 2014
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use